Favorable Outcomes in Patients Surviving 5 or More Years after Allogeneic Hematopoietic Stem Cell Transplantation for Hematologic Malignancies  Robert Quan Le, Margaret Bevans, Bipin N. Savani, Sandra A. Mitchell, Kate Stringaris, Eleftheria Koklanaris, A. John Barrett  Biology of Blood and Marrow Transplantation  Volume 16, Issue 8, Pages 1162-1170 (August 2010) DOI: 10.1016/j.bbmt.2010.03.005 Copyright © 2010 Terms and Conditions

Figure 1 Primary disease-free survival and probability of relapse or death in patients beyond 5-year post-HSCT. (A) Primary disease-free survival. Ninety two (35%) of 262 patients survived the first 5-year post-HSCT. Seventy-three (27.9%) patients had disease relapsed before 5-year-post-HSCT. Eighty patients were primary disease free at the 5-year post-HSCT. (B) Probability of relapse or death. The estimated probability of primary disease relapse at 10 years and 15 years was 6.2% and 17.9%, respectively. The estimated probability of mortality at 10 years and 15 years was 5.8% and 16%, respectively. Biology of Blood and Marrow Transplantation 2010 16, 1162-1170DOI: (10.1016/j.bbmt.2010.03.005) Copyright © 2010 Terms and Conditions